| Brand name |
nogapendekin alfa inbakicept
|
|---|---|
| المخاطر |
Management of adverse reactions and particularly Immunological adverse reactions. To ensure the safe use of ANKTIVA in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), and to minimize the risks of injection site reactions, liver dysfunction, respiratory and cardiac complications, immune-mediated adverse reactions, and cytokine release syndrome. |
| تاريخ الموافقة |
|
| Educational materials for healthcare practitioners | |
| المواد التعليمية الموجهة للمريض |
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 13 Aug 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Official Reliable websites use HTTPS
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.